Scale for chemotherapy-induced long-term neurotoxicity (SCIN):: Psychometrics, validation, and findings in a large sample of testicular cancer survivors

被引:86
作者
Oldenburg, Jan [1 ]
Fossa, Sophie D.
Dahl, Alv A.
机构
[1] Univ Oslo, Rikshosp, Dept Clin Canc Res, Radiumhosp Trust, N-0310 Oslo, Norway
[2] Univ Oslo, Fac Med, N-0310 Oslo, Norway
关键词
chemotherapy; cisplatin; neurotoxicity; ototoxicity; patient-based rating; rating; scale;
D O I
10.1007/s11136-005-5370-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Neurotoxicity is common after modern chemotherapy, and can be assessed both objectively and subjectively based on symptoms reported by patients. The aim of this study was to explore the psychometric properties of a brief self-report scale for chemotherapy induced long-term neurotoxicity (the SCIN). Methods: As part of a questionnaire survey 684 testicular cancer survivors (TCSs) filled in the SCIN, which assesses peripheral sensory neuropathy (paresthesias), Raynaud's phenomenon, and ototoxicity. Factor structure and internal consistency reliability of the SCIN were tested by the split-half method. In 538 TCSs, audiogram data were compared to the patients SCIN ratings of hearing. Results: The internal consistency of the SCIN showed a Cronbach's alpha of 0.72. The three-factor structure of the SCIN was confirmed with 77% explained variance. All the SCIN items discriminated significantly between the TCSs who had been treated with cisplatin-based chemotherapy vs. those who did not receive such treatment. The individual cumulative cisplatin dose correlated significantly with all the SCIN items. The Pearson product-moment correlation coefficient was 0.54 between hearing reduction at 4000 Hertz measured by audiogram and the SCIN self-report of reduced hearing. Conclusion: The SCIN shows good psychometric properties, and is recommended as a brief screening instrument for chemotheraphy-indeed neurotoxicity.
引用
收藏
页码:791 / 800
页数:10
相关论文
共 34 条
[1]   BLEOMYCIN AND RAYNAUDS-PHENOMENON [J].
ADOUE, D ;
ARLET, P .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :770-770
[2]   Tinnitus in the older adult - Epidemiology, pathophysiology and treatment options [J].
Ahmad, N ;
Seidman, M .
DRUGS & AGING, 2004, 21 (05) :297-305
[3]   Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy [J].
Barajon, I ;
Bersani, M ;
Quartu, M ;
DelFiacco, M ;
Cavaletti, G ;
Holst, JJ ;
Tredici, G .
EXPERIMENTAL NEUROLOGY, 1996, 138 (01) :93-104
[4]   Raynaud's phenomenon [J].
Block, JA ;
Sequeira, W .
LANCET, 2001, 357 (9273) :2042-2048
[5]   Evaluation of long-term toxicity after chemotherapy for testicular cancer [J].
Bokemeyer, C ;
Berger, CC ;
Kuczyk, MA ;
Schmoll, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) :2923-2932
[6]   Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer [J].
Bokemeyer, C ;
Berger, CC ;
Hartmann, JT ;
Kollmannsberger, C ;
Schmoll, HJ ;
Kuczyk, MA ;
Kanz, L .
BRITISH JOURNAL OF CANCER, 1998, 77 (08) :1355-1362
[7]  
BOYER M, 1992, SEMIN ONCOL, V19, P128
[8]  
Brand F N, 1997, Vasc Med, V2, P296
[9]   Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy [J].
Calhoun, EA ;
Welshman, EE ;
Chang, CH ;
Lurain, JR ;
Fishman, DA ;
Hunt, TL ;
Cella, D .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (06) :741-748
[10]   Measuring the side effects of taxane therapy in oncology - The functional assessment of cancer therapy-taxane (FACT-taxane) [J].
Cella, D ;
Peterman, A ;
Hudgens, S ;
Webster, K ;
Socinski, MA .
CANCER, 2003, 98 (04) :822-831